ImmuCell Corporation
ICCC
$9.77
-$0.15-1.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.49% | 9.64% | 4.34% | 16.49% | 21.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.49% | 9.64% | 4.34% | 16.49% | 21.75% |
| Cost of Revenue | 3.50% | -6.10% | -12.68% | -3.19% | 6.26% |
| Gross Profit | 16.82% | 41.66% | 44.13% | 64.87% | 60.96% |
| SG&A Expenses | 38.02% | 17.42% | 4.77% | 8.18% | 3.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.00% | -3.24% | -10.44% | -4.27% | -0.11% |
| Operating Income | 169.15% | 1,583.60% | 249.33% | 185.05% | 151.80% |
| Income Before Tax | -51.85% | -100.31% | 52.09% | 161.43% | 143.83% |
| Income Tax Expenses | 497.30% | 111.43% | 17.17% | 175.00% | 170.73% |
| Earnings from Continuing Operations | -55.30% | -100.70% | 51.78% | 160.98% | 143.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.30% | -100.70% | 51.78% | 160.98% | 143.51% |
| EBIT | 169.15% | 1,583.60% | 249.33% | 185.05% | 151.80% |
| EBITDA | 59.28% | 137.85% | 394.65% | 10,191.97% | 798.67% |
| EPS Basic | -54.03% | 4.90% | 59.52% | 153.32% | 136.16% |
| Normalized Basic EPS | 244.03% | 414.20% | 184.68% | 152.97% | 128.54% |
| EPS Diluted | -59.06% | 4.14% | 59.17% | 150.64% | 134.48% |
| Normalized Diluted EPS | 241.22% | 413.15% | 184.27% | 152.97% | 128.54% |
| Average Basic Shares Outstanding | 3.11% | 6.73% | 10.54% | 14.35% | 13.05% |
| Average Diluted Shares Outstanding | 3.87% | 7.15% | 10.99% | 14.35% | 13.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |